Enterovirus Acute Flaccid Myelitis











Associate Professor of Pediatric Infectious Diseases University of Colorado/ Children's Hospital Colorado

(kevin.messacar@childrenscolorado.org, @kmess44)



Disclosures

- No relevant financial disclosures or conflicts of interest
 - Supported by NIAID K23AI28069

I will discuss off-label use of medications

Please refrain from taking photos of any slides with the icon in the corner.



Fall 2014:







Fall 2014 Children's Hospital CO: An Unexpected Strain


Observed ValueExpected Value (SARIMA modeling)---95% Confidence Interval of Expected

- •1185 Excess
 Respiratory ED
 Visits
- •387 Excess Respiratory Admissions
- 96 ExcessRespiratory PICUAdmissions




The Unexpected Guest









Enterovirus D68


- Discovered 1962 in respiratory specimens from children with pneumonia
- Non-polio EV: biological and clinical properties similar to rhinoviruses
- Can be acid labile
 - Unlike other EVs, broken down in GI tract and rarely detected in stool
- Optimal growth at 33°C
 - Transmitted by respiratory droplet, causes primarily respiratory disease





Case Definition: Acute Flaccid Myelitis

- Clinical criteria: Acute onset flaccid limb weakness (AFP)
- + Imaging criteria: MRI with spinal cord lesion largely restricted to gray matter and spanning one or more spinal segments ("confirmed")



Children's Hospital Colorado

Outline



Epidemiology



Natural History



Diagnosis




Treatment



Rehabilitation




Outcomes



Research Developments
....Future Challenges



US AFM Epidemiology: 2014 - 2019




- 2014: 120 cases
 - 34 states
- 2015: 22 cases
 - 17 states
- 2016: 153 cases
 - 39 states
- 2017: 38 cases
 - 17 states
- 2018: 238 cases
 - 42 states
- 2019: 47 cases
 - 18 states







Temporal Association Between AFM Cases and EV-D68 Circulation in US



EV-D68 Surveillance at CHCO: Aurora, CO



Epidemiologic Modeling: EV-D68 Driving AFM Seasonal Biennial Spikes in US








Global AFM Epidemiology

Twenty-nine Cases of Enterovirus-D68–associated Acute Flaccid Myelitis in Europe 2016

A Case Series and Epidemiologic Overview

Marjolein Knoester, MD, PhD,* Jelte Helfferich, MD,† Randy Poelman, MSc,*
Coretta Van Leer-Buter, MD, PhD,* Oebele F. Brouwer, MD, PhD,† and Hubert G. M. Niesters, PhD,*
on Behalf of the 2016 EV-D68 AFM Working Group





Chong, P. F., et al. (2017). "Clinical Features of Acute Flaccid Myelitis Temporally Associated with an Enterovirus D68 Outbreak: Results of a Nationwide Survey of Acute Flaccid Paralysis in Japan, August-December 2015." *Clin Infect Dis.* The United Kingdom Acute Flaccid Paralysis Afp Task, F. (2019). "An increase in reports of acute flaccid paralysis (AFP) in the United Kingdom, 1 January 2018-21 January 2019: early findings." *Euro Surveill* 24(6).



Global Recognition of EV-D68 AFM

Reported AFP/AFM Cases with EV-D68 in Biologic Specimens

Country	# Cases (Year of Presentation)
Argentina	4 (2016)
Australia	2 (2010)
Canada	7 (2014)
China	1 (2018)
Denmark	1 (2019)
DR Congo	1 (NR)
France	2 (2014), 5 (2016), 1 (2019)
Germany	2 (2016), 1 (2019)
United Kingdom	1 (2014), 2 (2015), 6 (2016), 9 (2018)
Italy	2 (2016)
Japan	3 (2013), 9 (2015), 1 (2017)
Netherlands	2 (2016)
Norway	2 (2014), 3 (2016)
Senegal	3 (2016)
Spain	1 (2015), 4 (2016), 1 (2017), 2 (2018)
Sweden	3 (2016)
United States	1 (2005), 1 (2008), 1 (2009), 4 (2012),
	12 (2014), 22 (2016), 30 (2018)




>150 cases in 20 countries on 6 continents

Messacar, K., et al. (2018). "Enterovirus D68 and acute flaccid myelitis-evaluating the evidence for causality." *Lancet Infect Dis.*

Updated with new reported cases since publication

What Happened in 2020?

What Will Happen in 2020 and Beyond?






Park SW, Farrar J, Messacar K, Meyers L, Pons-Salort M, Grenfell BT. Epidemiological dynamics of enterovirus D68 in the US: implications for acute flaccid myelitis. *Science TM* 2021.



Children's Hospital Colorado




Advances in Preparedness: Epidemiologic Modeling








Advances in Preparedness: Epidemiologic Modeling





AFM Natural History



neck pain

in the limb(s)

AFM Diagnosis


AFM Diagnostic Studies

- Neurologic exam: flaccid weakness
- Brain/spinal cord MRI: longitudinal gray matter +/brainstem lesions
- Lumbar puncture: CSF pleocytosis



AFM Etiologic Evaluation


Early biological specimen collection





AFM: Treatment

- No controlled studies of treatment efficacy in humans
 - Immunomodulatory therapies commonly administered
 - IVIG: high neutralizing Ab titers to EV-D68
 - Monoclonal EV-D68 Abs created, undergoing testing
 - Steroids: recommended when spinal cord edema→UMN signs due to compression
 - Antivirals: No available anti-EV medications
 - Polio antivirals in dev't with EV-D68, EV-A71 activity



- 2016: Fluoxetine administered off-label due to in vitro EV-D68 activity
 - No signal of efficacy in retrospective analysis of limb strength outcomes in tx'd (n=26) vs. untx'd (n=26)



AFM Therapies: Supportive Care

- Hospitalize all suspected cases presenting in the acute phase
- Review

- Monitor respiratory status
 - Ability to protect airway
 - Negative inspiratory flow
 - ➤ Intubation, ventilation for respiratory failure
- Monitor for constipation, urinary retention
 - ➤ Bowel regimen, catheterization
- Support hydration/nutrition
 - ➤ Enteral feeding

Acute flaccid myelitis: cause, diagnosis, and management

Olwen C Murphy, Kevin Messacar, Leslie Benson, Riley Bove, Jessica L Carpenter, Thomas Crawford, Janet Dean, Roberta DeBiasi, Jay Desai, Matthew J Elrick, Raquel Farias-Moeller, Grace Y Gombolay, Benjamin Greenberg, Matthew Harmelink, Sue Hong, Sarah E Hopkins, Joyce Oleszek, Catherine Otten, Cristina L Sadowsky, Teri L Schreiner, Kiran T Thakur, Keith Van Haren, Carolina M Carballo, Pin Fee Chong, Amary Fall, Vykuntaraju K Gowda, Jelte Helfferich, Ryutaro Kira, Ming Lim, Eduardo L Lopez, Elizabeth M Wells, E Ann Yeh, Carlos A Pardo; on behalf of the AFM working group*



AFM: Outcomes

- Functional improvements with rehabilitation therapies
 - Distal, less-affected muscles > proximal, more-affected muscles > completely denervated muscles
- Most recovery occurs early
 - Improvement still noted >12 mos
- Motor deficits persist in ~75%
 - Few completely recover




Polio-like muscle atrophy in affected limbs



Enterovirus A71 Myelitis

- Hand-foot-mouth disease outbreaks
- Brainstem encephalitis→noncardiogenic pulmonary edema
- Myelitis→flaccid limb weakness, meeting AFM case definition
- 1970s-: sporadic epidemics in N. America, Europe, Africa, Australia; now every 2-5 year epidemics in Asia-Pacific region
 - Ex: Taiwan 1998: 1.5 million infected, 405 with neuro ds
- Notable recent European outbreaks in France (2016), Spain (2017), and Germany (2019)

Bottcher S, et al.. Increased detection of enterovirus A71 infections, Germany, 2019. Euro surveillance: 2019; 24(39).











2018: Outbreak of EV-A71 Neurologic Disease in CO Children

- May 2018: Increase in EV-associated neurologic cases
 - Specimens typed at EV-A71 at CDC
- N=43 cases of EV-A71 neurologic disease, including 10 AFM cases





EV-D68 Associated AFM Cases


Respiratory prodrome



EV-A71 Associated AFM Cases

Fever, ~1/2 HFMD prodrome






EV-D68 Associated AFM Cases

- Respiratory prodrome
- Limb weakness +/- CN dysfcn


- Fever, ~1/2 HFMD prodrome
- +myoclonus, ataxia, autonomic sx







EV-D68 Associated AFM Cases

- Respiratory prodrome
- Limb weakness +/- CN dysfcn
- Gray matter-predom myelitis



- Fever, ~1/2 HFMD prodrome
- +myoclonus, ataxia, autonomic sx
- Indistinguishable from EV-D68







EV-D68 Associated AFM Cases

- Respiratory prodrome
- Limb weakness +/- CN dysfcn
- Gray matter-predom myelitis
- † detection in NP specimens




- Fever, ~1/2 HFMD prodrome
- +myoclonus, ataxia, autonomic sx
- Indistinguishable from EV-D68
- Detected in rectal/stool>OP>NP







EV-D68 Associated AFM Cases




- Majority: persistent weakness
 Majority: complete recovery



AFM Pathophysiology: EV-D68 Causes AFM in Mice






EV-D68 strains tested that caused paralysis in neonatal mice:


US/MO/14-18947 (i.m., i.c., i.p., i.n.)

US/IL/14-18952 (i.c. tested)

US/KY/14-18953 (i.c. tested)

US/CA/14-4232 (i.c. tested)






(+) Spinal cord lysate from paralyzed mouse caused paralysis in naïve animals





C. Viral titer assays:



(+) EV-D68 infectious virus detected by cell culture assays and EV-D68 viral genome detected by qRT-PCR and metagenomic deep sequencing



(+) EV-D68 VP2 protein in motor neurons followed by neuron loss




Research Advances in AFM Tx: Mouse Model Treatment Efficacy








- Fluoxetine: No effect
- Steroids: Increased viral titers in spinal cord, worsened motor impairment, increased mortality





Monoclonal EV-D68 Ab: Improved outcomes>IVIG, even out to 48-72 hrs post




Advances in Treatment: Mouse Model Treatment Efficacy








AFM Pathophysiology: EV-D68 Infects Neurons









Advances in Pathophysiology: EV-D68 infects spinal cord motor neurons in human AFM



- Fall 2008: 5yo boy developed flaccid paralysis and respiratory failure following nonspecific viral illness
- Autopsy findings demonstrated Tlymphocyte inflammation in anterior spinal cord and neuronophagia
 - CSF +EV-D68 by PCR
- Subsequent analysis stained EV-D68 RNA and protein in anterior horn motor neurons of spinal cord



AFM Pathophysiology: EV-D68 Retrograde Axonal Transport








Research Advances in AFM Dx: Panviral Antibody Testing of CSF

- New phage display serologic assays and microarray chip technologies can look for Abs to many viral peptides in CSF
 - High levels of EV Ab detected in CSF of most AFM cases vs. controls (including patients without virus identified in CSF or nonsterile sites)
 - No Abs to other viruses consistently identified


➤ Detection of EV Ab in CSF may become clinical diagnostic test for EV AFM, similar to other neuroinvasive viruses (ie. WNV)






Advances in Preventio Vaccine Development

- Vaccines can effectively prevent EV disease
 - Poliovirus vaccines, global eradication campaign
 - EV-A71 vaccines licensed in China
 - Efficacy against HFMD, severe disease
- Few EV-D68 candidate vaccines in early pre-clinical stages of development
 - VLP Vaccine (China)
 - NIH Vaccine Research Center
 - Intravacc received NIAID contract to dev'p vax





EV-D68 VLP Vaccine:

Maternal vaccination completely protects neonatal mice from lethal infection


Ongoing Research Efforts: NIAID Multicenter AFM Natural History Study



- 36+ center international (US, Canada, UK, Peru) study of children with suspected AFM and household contacts followed over 1 year to determine natural history and populate NIAID biorepository for AFM research
 - Samples and data accessible through oversight committee

Ongoing Research Efforts: PREMISE EV-D68 Pilot Study

- PREMISE: pathogen-agnostic NIAID pandemic preparedness project to create immunologic biorepository at NIAID Vaccine Research Center
 - Creation of on-the-shelf tools (diagnostics, therapeutics, vaccines) for emerging infectious diseases
- EV-D68 Pilot: focused proof-ofprinciple study using virus with public health importance likely to re-emerge
 - To enroll 500 children <10yo at 4 US sites for collection of pre- and post-EV season blood specimens (serum, plasma, pBMCs)
 - Followed with symptom surveys during EV season to collect respiratory specimen when sx



Future Vision:

Comprehensive EV-D68 AFM Surveillance



Syndromic Surveillance



AFM Epidemiology Etiologic Investigation



Symptomatic Surveillance

Respiratory Disease

EV-D68 Epidemiology Outbreak Detection Burden of Disease



Wastewater Surveillance

Asymptomatic Infection


Early Warning System Phylodynamic Monitoring



Prior Exposure/ Immunity

Modeling Preparedness

Future Vision: Global EV Surveillance




Global Integration of EV Surveillance Networks


Inclusion of respiratory sampling in polio surveillance

Real-time Global Sharing of Surveillance Data

- Epidemiological data
- Phylodynamics



Prepared for the Present



Severe Respiratory Illnesses Associated with Rhinoviruses and/or Enteroviruses Including EV-D68 – Multistate, 2022







To: All Children's Hospital Colorado team members

Dear team members,

Over the past few weeks, emergency departments across our System of Care have seen a significant rise in acute respiratory disease, particularly astitypically see, leading to high numbers of hospital admissions due to respiratory issues. Our monthly census for occupied beds was the highest it has be working around-the-clock to ensure we have the ability to care for all of these patients.

CDC warns about enterovirus in kids — and the risk of rare paralysis that can follow

BY ALEXANDER TIN UPDATED ON: SEPTEMBER 12, 2022 / 5:39 PM / CBS NEWS

Our infectious disease and laboratory professionals have identified Enterovirus D-68 (EV-D68) as a contributing factor behind this surge of respiratory unsease, and other pediatric nospital systems around the country are seeing similar trends. Ever book tends to ronow a piermian outbreak pattern and nation in which is used to represent the past two years of the pandemic.

42

In addition to causing respiratory disease, EV-D68 can cause limb weakness due to the polio-like neurologic disease, Acute Flaccid Myelitis (AFM). Based on prior EV-D68 waves, we anticipate that we may see a rise in AFM cases in the weeks to come. Given our clinical and research expertise in this area, Children Hospital Colorado is well-equipped and prepared to provide the best care to any child affected. We will be working closely with the Centers for Disease Control and Prevention and Colorado Department of Public Health and Environment to support the public health response.

Challenges for the Future


- Improved AFM recognition: early diagnosis, specimen collection, care
 - ➤ Limb weakness in setting of febrile illness (esp during EV season): Suspect AFM
 - > MRI + LP to confirm
 - ➤ Collect CSF, blood, NP/OP, rectal/stool specimens
- Improved surveillance: AFM and EVs
 - ➤ Reporting systems for all suspected AFM cases
 - ➤ Active EV surveillance for early warning system, preparedness
- Improved understanding of pathophysiology
 - ➤ NIH prospective multicenter AFM Natural History Study enrolling in US/UK/Peru
- Improved treatment and prevention strategies
 - ➤ Therapeutic candidates evaluated in animal and laboratory models
 - Vaccine candidate identification



AFM is currently uncommon, but has serious long-term morbidity



"Watching healthy children become permanently paralyzed virtually overnight by a seemingly random, lightning-strike disease is as heartbreaking today as it was in the polio era. The trajectory of AFM over the past 5 years suggests that the problem is getting worse, and so it is critical that we galvanize our efforts to learn more about, and respond adequately to, this ubiquitous, often crippling, continually reemerging group of viruses."



Recognize AFM early

Be alert for onset of acute flaccid limb weakness and consider AFM on your differential diagnosis

Collect specimens & then get MRI

Collect
cerebrospinal fluid
(CSF), serum, stool,
and nasopharyngeal
(NP) swab as soon
as possible, and
handle and store
specimens properly

Rapidly report to health department

If the MRI shows a spinal lesion with some gray matter involvement, alert the health department and send specimens and medical records

Diagnosis & medical management

Refer to specialists, monitor for signs of worsening symptoms, hospitalize if indicated, and begin treatment and rehabilitation



Take Home Points

- THINK AFM in any patient with new onset weakness, particularly:
 - Children with asymmetric, flaccid weakness
 - Following a **febrile respiratory illness**
 - Summer-fall season during enterovirus outbreaks
- DIAGNOSE AFM by neurologic exam, neuroimaging, lumbar puncture
 - Collect early biologic specimens (CSF, blood, stool, NP/OP) to look for cause
- MANAGE AFM with respiratory & neurologic supportive care, rehabilitation
 - Reach out for help from neurology and infectious disease consultants
- REPORT AFM to your state health department as soon as you suspect it
 - **Submit requested biological specimens** using CDC Job Aid (https://www.cdc.gov/acute-flaccid-myelitis/hcp/clinicians-health-departments.html)



KEY REFERENCES

Messacar K, Schreiner TL, Van Haren K, et al. Acute flaccid myelitis: A clinical review of US cases 2012-2015. *Annals of neurology* 2016; **80**(3): 326-38.

Harvala H, Broberg E, Benschop K, et al. Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. *Journal of clinical virology*. 2018;101:11-17.

McLaren N, Lopez A, Kidd S, et al. Characteristics of Patients with Acute Flaccid Myelitis, United States, 2015-2018. *Emerging infectious diseases* 2020; **26**(2).

Murphy OC, Messacar K, Benson L, et al. Acute flaccid myelitis: cause, diagnosis, and management. *Lancet* 2021; **397**(10271): 334-46.



RESOURCES

US CDC Resources for clinicians/public health: https://www.cdc.gov/acute-flaccid-myelitis/hcp/clinicians-health-departments.html

AFM Working Group Resources for clinicians: https://acuteflaccidmyelitis.org/

Acute Flaccid Myelitis Association Resources for Parents: https://www.afmanow.org/

